We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Computer System Launched To Manage Blood Screening Data

By LabMedica International staff writers
Posted on 21 Oct 2008
A computer system was launched that improves laboratory efficiency by managing test data when screening donated blood for hepatitis and retroviruses.

The new system will enable laboratories to track and trend quality control and performance of blood-screening assays and will provide laboratories with robust data capabilities through expanded archival features. More...
It also will help blood-screening laboratories manage retesting of samples, produce reports, and generate statistical charts.

Called the Abbott Prism Director, the new system was launched by Abbott (Abbott Park, IL, USA) at the American Association of Blood Banks annual meeting on October 7, 2008, in Montreal, Canada. The Abbott Prism is an automated immunoassay analyzer designed to perform in vitro diagnostic donor screening for hepatitis and retroviruses. The analyzer is used by blood, plasma, organ, and tissue centers in more than 30 countries to screen more than 40 million donations each year.

"The worldwide launch of the Abbott Prism Director brings an important new product to our expanding portfolio of blood-screening systems and assays and demonstrates our continued commitment to blood-screening laboratories and the overall safety of the blood supply,” said James Stewart, Ph.D., director of research and development, Abbott Diagnostics. "For testing facilities that use multiple or single Abbott Prism instruments, the Abbott Prism Director offers data management functionality that can significantly enhance laboratory operations.”

Abbott is a global leader in in vitro diagnostics and provides a broad range of instrument systems and tests for hospitals, reference labs, molecular labs, blood banks, physician offices, and clinics. The company's diagnostic products offer customers automation, convenience, bedside testing, cost effectiveness, and flexibility.

Related Links:
Abbott


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Automatic Hematology Analyzer
CF9600
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
All-in-One Molecular System
AIO M160
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: New findings demonstrate that anti-Müllerian hormone (AMH) may help identify which breast cancer patients are most likely to benefit from chemotherapy plus endocrine therapy (Image Credit: Shutterstock)

AMH Test Helps Predict Adjuvant Chemotherapy Benefit in Premenopausal Breast Cancer

Hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer can present a difficult treatment decision in premenopausal patients with low recurrence scores.... Read more

Molecular Diagnostics

view channel
Image Credit: iStock

Sequencing-Based Newborn Screening Identifies Pediatric Cancer Risk at Birth

Newborn screening in the United States relies on heel-stick blood spots to identify rare, treatable disorders through biochemical testing, but these programs generally do not assess inherited cancer risk... Read more

Microbiology

view channel
Image: The QIAstat-Dx BCID GPF Plus AMR Panel is the first QIAstat-Dx panel for bloodstream infections to receive FDA clearance (Photo courtesy of Qiagen)

FDA Clears One-Hour Panel for Bloodstream Infection and AMR Detection

Bloodstream infections can rapidly progress to sepsis, a life-threatening condition affecting an estimated 1.7 million adults in the U.S. each year. Rapid identification of pathogens and antimicrobial... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.